Braxia Scientific Corp

CNSX:BRAX

Braxia Scientific Corp. engages in the cultivation, distribution, and proliferation of artensial, medicinal mushrooms, and derivatives. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2020-02-27. The firm is primarily focused on owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and research activities related to discovering and commercializing novel drugs and delivery method. The firm seeks to develop ketamine and derivatives and other psychedelic products from its Internet protocol (IP) development platform. The firm through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc. operates multidisciplinary community-based clinics offering treatments for depression located in Mississauga, Toronto, Ottawa, and Montreal. Its treatment includes Intravenous (IV) Ketamine, Intranasal (IN) Esketamine and Oral Ketamine Tablets. Its subsidiaries include Altmed, Tassili Life Science Corp. (TLS), Artisan Growers Ltd. (AGL), Novo Formulations Ltd. (NOVO) and Canadia Rapid Treatment Centre of Excellence (CRTCE).